The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
Algorithms
Angiopoietins
/ metabolism
Apolipoproteins
/ antagonists & inhibitors
Cardiovascular Diseases
/ etiology
Chylomicrons
/ metabolism
Fatty Acids, Omega-3
/ therapeutic use
Fibric Acids
/ therapeutic use
Genetic Predisposition to Disease
Humans
Hyperlipoproteinemia Type I
/ etiology
Hypertriglyceridemia
/ etiology
Hypolipidemic Agents
/ therapeutic use
Lipodystrophy, Familial Partial
/ complications
Lipoprotein Lipase
/ metabolism
Mutation
Oligonucleotides
/ therapeutic use
Pancreatitis
/ etiology
Receptors, Lipoprotein
/ genetics
Risk Factors
Journal
Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351
Informations de publication
Date de publication:
07 05 2019
07 05 2019
Historique:
pubmed:
30
4
2019
medline:
14
1
2020
entrez:
30
4
2019
Statut:
ppublish
Résumé
The chylomicronemia syndrome occurs when triglyceride levels are severely elevated (usually >16.95 mmol/L [1500 mg/dL]) and is characterized by such clinical features as abdominal pain, acute pancreatitis, eruptive xanthomas, and lipemia retinalis. It may result from 1 of 3 conditions: the presence of secondary forms of hypertriglyceridemia concurrent with genetic causes of hypertriglyceridemia, termed multifactorial chylomicronemia syndrome (MFCS); a deficiency in the enzyme lipoprotein lipase and some associated proteins, termed familial chylomicronemia syndrome (FCS); or familial partial lipodystrophy. Most chylomicronemia syndrome cases are the result of MFCS; FCS is very rare. In all these conditions, triglyceride-rich lipoproteins accumulate because of impaired plasma clearance. This review describes the 3 major causes of the chylomicronemia syndrome; their consequences; and the approaches to treatment, which differ considerably by group.
Identifiants
pubmed: 31035285
pii: 2732076
doi: 10.7326/M19-0203
doi:
Substances chimiques
Angiopoietins
0
Apolipoproteins
0
Chylomicrons
0
Fatty Acids, Omega-3
0
Fibric Acids
0
GPIHBP1 protein, human
0
Hypolipidemic Agents
0
Oligonucleotides
0
Receptors, Lipoprotein
0
Lipoprotein Lipase
EC 3.1.1.34
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM